Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Loading DCs with Ag.

F Vari1, D N J Hart

  • 1Mater Medical Research Institute, Queensland, South Brisbane, Australia.

Cytotherapy
|June 19, 2004
PubMed
Summary
This summary is machine-generated.

Dendritic cell (DC) biology advancements enable novel anti-cancer therapies. This review summarizes methods for delivering tumor antigens to DCs for effective cancer vaccine development and clinical application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBV-associated primary CNS lymphoma occurring after immunosuppression is a distinct immunobiological entity.

Blood·2020
Same author

The impact of HLA class I and EBV latency-II antigen-specific CD8(+) T cells on the pathogenesis of EBV(+) Hodgkin lymphoma.

Clinical and experimental immunology·2015
Same author

Immunosuppressive human anti-CD83 monoclonal antibody depletion of activated dendritic cells in transplantation.

Leukemia·2015
Same author

Practical blood dendritic cell vaccination for immunotherapy of multiple myeloma.

British journal of haematology·2008
Same author

Cord blood CD34+ cells cultured with FLT3L, stem cell factor, interleukin-6, and IL-3 produce CD11c+CD1a-/c- myeloid dendritic cells.

Stem cells and development·2007
Same author

DC preparations for therapy.

Cytotherapy·2004
Same journal

Dialysis bioreactor enables high-density, serum-free expansion of dental pulp-derived mesenchymal stromal cells with enhanced secretome.

Cytotherapy·2026
Same journal

Beyond the synapses: should we anticipate neurotransmitter signaling when manufacturing CAR-T cells for brain tumors?

Cytotherapy·2026
Same journal

Curative treatment for severe sickle cell disease: allogeneic hematopoietic cell transplant or gene therapy.

Cytotherapy·2026
Same journal

Manufacturing strategies for prolonged CAR-T cell persistence.

Cytotherapy·2026
Same journal

Overcoming five main challenges to targeting hematologic malignancies.

Cytotherapy·2026
Same journal

Mesenchymal stromal cell-based therapy in the COVID-19 pandemic: results from an academic phase I/II double-blind, randomized, placebo-controlled clinical trial and reflections for the field.

Cytotherapy·2026
See all related articles

Area of Science:

  • Immunology
  • Oncology
  • Biotechnology

Background:

  • Dendritic cells (DCs) are crucial for initiating and regulating immune responses.
  • Understanding DC biology has led to the development of effective anti-cancer therapies.
  • DC-based cancer vaccines are a promising area of research.

Purpose of the Study:

  • To review methods for delivering tumor antigens to dendritic cells (DCs).
  • To evaluate techniques for antigen delivery to DCs for cancer vaccine development.
  • To discuss the clinical applicability, advantages, and disadvantages of various antigen delivery methods.

Main Methods:

  • Literature review of existing studies on DC-based cancer vaccine development.
  • Analysis of different methods for delivering tumor antigens to DCs.

Related Experiment Videos

  • Evaluation of techniques used in antigen delivery and their clinical potential.

    • Main Results:

    • Numerous methods exist for delivering defined and undefined tumor antigens to DCs.
    • These methods aim to enhance antigen processing and presentation to T lymphocytes.
    • Each method has unique advantages and disadvantages for clinical use.

    Conclusions:

    • Effective antigen delivery to DCs is key for successful DC-based cancer vaccines.
    • Various delivery methods offer different clinical possibilities and challenges.
    • Further research and clinical evaluation are needed to optimize these therapies.